Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr-Reference-Cited by-同舟云学术

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr

Published:2013-12-30 Issue:7 Volume:120 Page:1002-1009
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Soverini Simona¹,De Benedittis Caterina¹,Papayannidis Cristina¹,Paolini Stefania¹,Venturi Claudia¹,Iacobucci Ilaria¹,Luppi Mario²,Bresciani Paola²,Salvucci Marzia³,Russo Domenico⁴,Sica Simona⁵,Orlandi Ester⁶,Intermesoli Tamara⁷,Gozzini Antonella⁸,Bonifacio Massimiliano⁹,Rigolin Gian Matteo¹⁰,Pane Fabrizio¹¹,Baccarani Michele¹,Cavo Michele¹,Martinelli Giovanni¹

Affiliation:

1. Department of Experimental, Diagnostic and Specialty Medicine; Institute of Hematology “L. e A. Seràgnoli,” University of Bologna; Bologna Italy

2. Department of Medical and Surgical Sciences; AOU Policlinico, UNIMORE; Modena Italy

3. Oncology-Hematology Department; “S. Maria delle Croci” Hospital; Ravenna Italy

4. Chair of Haematology, Unit of Blood Diseases and Stem Cell Transplantation; University of Brescia; Brescia Italy

5. Department of Hematology; Catholic University of the Sacred Heart; Rome Italy

6. Division of Hematology, Fondazione IRCCS Policlinico San Matteo; University of Pavia; Italy

7. U.S.C. Ematologia; Ospedali Riuniti di Bergamo; Bergamo Italy

8. Division of Hematology; AOU Careggi; Florence Italy

9. Department of Medicine, Section of Hematology; University of Verona; Verona Italy

10. Institute of Hematology, Department of Biomedical Sciences; AOU Sant'Anna; Ferrara Italy

11. Haematology Unit and Department of Biochemistry and Medical Biotechnology, CEINGE-Advanced Biotechnology; University of Naples “Federico II”; Naples Italy

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28522/fullpdf

Reference40 articles.

1. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol;Vignetti;Blood,2007

2. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL);Ottmann;Cancer,2007

3. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate;Thomas;Blood,2004

4. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia;Lee;Leukemia,2005

5. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group;Yanada;J Clin Oncol,2006

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB‐positive acute lymphoblastic leukemia patients: A retrospective multicenter study;Cancer;2024-08-13

2. Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasms;Frontiers in Pharmacology;2024-07-22

3. Chemotherapy-free treatment of VAF induces early and deep molecular response in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective, single-center, single-arm, phase 2 trial;2024-07-12

4. Mutation and cell state compatibility is required and targetable in Ph+acute lymphoblastic leukemia minimal residual disease;2024-06-10

5. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia;JAMA;2024-06-04